Cytoagents logo final cmyk
Cytoagents logo final cmyk

CytoAgents

CytoAgents is a clincal-stage biotech company creating a platform to treat viral epidemics and global pandemics like COVID-19.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Pittsburgh, PA, USA
  • Currency USD
  • Founded December 2018
  • Employees 4
  • Incorporation Type C-corp
  • Website cytoagents.com

Company Summary

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment the of life-threatening symptoms associated with Cytokine Releasing Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS; our mission is to develop a broadly accessible treatment for multiple indications of high unmet need.

Team

  • Teresa Whalen, CEO is a pharmacist by trade and has 25+ years of experience in the healthcare industry. She is a proven leader in the areas of sales leadership, developing go to market strategies and managing strategic partnerships. She is a seasoned executive with experience spanning large companies, Siemens Medical, to startups with successful exits. She is focused on strategy, business funding and developing strategic partnerships.

  • Default avatar
    Todd Lorenz, MD
    Chief Medical Officer

    Todd Lorenz, a physician with over 20 years of drug development experience running large scale global trials and bringing drugs to the market. Todd has experience at large pharma and small biotech companies including J&J, Cor Therapeutics, Orexigen, Catalyst Biosciences and Corgentech.

  • Default avatar
    Jodi Craigo, PhD
    Chief Science Officer

    Jodi Craigo, our Chief Science Officer and a PhD in Cellular and Molecular Biology with over 20 year of experience at the University of Pittsburgh studying Virology and Immunology, most recently served as the Director of Operations at Pitts Vaccine Research Center.

  • 711264ac e075 4855 9c5e d6ba98ed67e6
    Chief Financial Officer

    Roy Prieb is an entrepreneur with over 20 years of experience in building innovative technology and life sciences companies. Most recently, he was a co-founder and director of Kleo Pharmaceuticals, a synthetic immunotherapy company spun out from Yale University. He served as the company's COO/CFO. Roy worked as a management consultant with Boston Consulting Group. He received his BA from Harvard College and MBA from Wharton Business School.

  • Default avatar
    Jim Nolan
    Business Development

    Jim brings over 35 years of experience in the Pharmaceutical Industry. He is a Partner of both IPD, a drug discovery company, where he is CEO, and Velocity Fund Partners. Since beginning his pharmaceutical career with Dow Chemical and Chairing Research at Wyeth Jim has been involved in all aspects of our industry, in the US and internationally. Jim has an in-depth understanding of how to plan, fund, develop and bring a new products to market.

Advisors

  • Default avatar
    Dr. Michael Ison, MD, MS Board Certified Infectious Disease Northwestern
    Unconfirmed
    Default avatar
    Dr. Paul Thomas, PhD Full Member, Dept. of Immunology St. Jude Children's Research Hospital
    Unconfirmed
    Default avatar
    Dr. Albert Osterhaus, PhD Chair EU Group on Influenza > 1,200 publications
    Unconfirmed
  • Default avatar
    Dr. Hank Safferstein, PhD, JD, MBA EIR UPMC Enterprises CEO Generian
    Unconfirmed

Previous Investors

  • Default avatar
    Blue Tree Allied Angels
    Unconfirmed
    Default avatar
    Innovation Works
    Unconfirmed
    Default avatar
    Next Act Fund
    Unconfirmed
  • Default avatar
    Delaware Crossing
    Unconfirmed
    Default avatar
    Pittsburgh Life Sciences Greenhouse
    Unconfirmed